Fat malabsorption impacts millions of people that have conditions or diseases affecting the pancreas, liver, or intestine. It leads to nutrient deficiencies, and causes chronic GI symptoms and long-term health issues. This is an unaddressed need, with existing products offering limited clinical benefit and suboptimal outcomes.
Branch Venture Group is excited to support Vytala, a Philadelphia-based clinical nutrition company that is launching Seracal, a breakthrough solution to help the 1.5 billion people suffering from fat malabsorption. Seracal delivers the needed, healthy fats and enhances absorption of other fat-soluble nutrients without relying upon digestive enzymes. Vytala is tackling a multi-billion-dollar market with a clinically validated, reimbursement-ready product and a bold vision to redefine both medical and everyday nutrition.
Here are four key reasons we believe Vytala is a standout investment opportunity.
Novel Product with a large market and strong potential for expansion
Vytala’s lead product, Seracal, incorporates structured lipid technology that improves fat and nutrient absorption in people with digestive challenges, many of whom are struggling to maintain proper weight. Pancreatic enzyme replacement therapy (PERT), commonly prescribed for malabsorption, is expensive, difficult to dose, and can be inconsistent, according to clinicians. Seracal provides a promising new option that can be used by itself, or alongside existing treatments.
Looking forward, Vytala plans to develop a suite of additional products with its structured lipid platform. The company will pursue new markets and categories (e.g., infant nutrition, cancer care, sports performance, and animal health), growing a single-product brand into a broad-based clinical nutrition platform.
Validated technology with compelling clinical evidence
Seracal’s efficacy has been demonstrated in a randomized, NIH-funded clinical trial. Patients in the trial saw improvements in fat absorption, BMI, and essential nutrient levels. This clinical proof sets Vytala apart from many other nutrition startups. It gives Seracal significant credibility with clinicians and payers, paving the way for adoption and reimbursement. It also strengthens the company’s position as the first mover in this new category, giving Vytala a strong head-start vs. potential competitors.
Established reimbursement and distribution infrastructure
Reimbursement is often a barrier to adoption in medical nutrition, but Vytala has already cleared that hurdle. Seracal is classified as by the FDA as a medical food, and Vytala management also applied & received a new CMS reimbursement code that enables Seracal to be reimbursed for a wide range of health conditions. This reimbursement pathway gives clinicians confidence in prescribing Seracal and ensuring patient access without financial burden.
Vytala has also partnered with a leading national complex care provider to manage billing, product fulfillment and patient support. This partnership allows the company to scale efficiently, minimizing overhead and facilitating payment collection. It streamlines Vytala’s operations and provides further credibility with healthcare providers.
Strong early traction and promising commercial model
Following the soft launch of Seracal in late 2024, Vytala has generated strong interest and uptake from clinicians and patients. Early feedback has been overwhelmingly positive, with clinicians noting weight gain across diagnoses, and in some patients that had not been able to gain weight in years. Multiple leading children’s hospitals have hosted meetings with Vytala and are placing orders for Seracal. One provider that has been trialing Seracal with patients is considering making it a standard of care.
Orders and margin have exceeded company forecasts, while monthly customer reorder rate has exceeded 90%. Seracal is a recurring-use product, so the lifetime value of a customer is significant. These early signals suggest both strong demand and long-term commercial potential.
Want to learn more about vytala?
We’re thrilled to back the Vytala team as they expand their clinical footprint and build out their portfolio of medical nutrition products. With a seasoned leadership team, a validated platform, and a clear commercialization roadmap, Vytala is well-positioned to improve outcomes for millions of patients. To learn more about Vytala, visit their website or follow them on LinkedIn. If you’re interested in hearing more about our work at Branch Venture Group, check out our Investor page or reach out to us at info@branchventuregroup.com.